Persistent Cervical Cancer
Drug | Drug Name | Drug Description |
---|---|---|
DB00112 | Bevacizumab | A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. |
DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB00112 | Bevacizumab | 2 | Recruiting | 1 |
DB08875 | Cabozantinib | 2 | Terminated | 1 |
DB14776 | Camrelizumab | 2 | Recruiting | 1 |
DB00958 | Carboplatin | 2 | Recruiting | 1 |
DB00515 | Cisplatin | 2 | Recruiting | 1 |
DB01229 | Paclitaxel | 2 | Recruiting | 1 |
DB09037 | Pembrolizumab | 2 | Terminated | 1 |
DB14765 | Rivoceranib | 2 | Recruiting | 1 |